Alector Reports Third Quarter 2025 Financial Results and Provides Business Update
Alector, Inc. (ALEC)
Last alector, inc. earnings: 3/24 04:05 pm
Check Earnings Report
Company Research
Source: GlobeNewswire
Selected lead candidates AL137 for the company’s Alector Brain Carrier (ABC)-enabled anti-amyloid beta antibody in Alzheimer's disease, and AL050 for its ABC-enabled GCase enzyme replacement therapy in Parkinson’s disease; both advancing toward IND-enabling studies Advancing ABC-enabled Tau, Alpha Synuclein and NLRP3 siRNA programs targeting peripheral delivery of novel therapies for neurodegenerative disorders Independent interim analysis for the PROGRESS-AD Phase 2 clinical trial of nivisnebart (AL101) in early Alzheimer’s disease planned for 1H 2026 $291.1 million in cash, cash equivalents, and investments provides runway through 2027 SOUTH SAN FRANCISCO, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today reported third quarter 2025 financial results and recent portfolio and business updates. As of September 30, 2025
Show less
Read more
Impact Snapshot
Event Time:
ALEC
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ALEC alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALEC alerts
High impacting Alector, Inc. news events
Weekly update
A roundup of the hottest topics
ALEC
News
- Alector to Participate in the Bank of America CNS Therapeutics Conference [Yahoo! Finance]Yahoo! Finance
- Alector to Participate in the Bank of America CNS Therapeutics ConferenceGlobeNewswire
- ALEC Investors Have Opportunity to Join Alector, Inc. Fraud Investigation with the Schall Law FirmGlobeNewswire
- ALEC Investors Have Opportunity to Join Alector, Inc. Fraud Investigation with the Schall Law FirmGlobeNewswire
- ALEC Investors Have Opportunity to Join Alector, Inc. Fraud Investigation with the Schall Law FirmBusiness Wire
ALEC
Earnings
- 11/6/25 - Beat
ALEC
Sec Filings
- 12/3/25 - Form 4
- 12/3/25 - Form 4
- 12/3/25 - Form 4
- ALEC's page on the SEC website